ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • By

  • June 14, 2026

  • 4 min

Share

Original Source(s)

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

  • by

  • June 14, 2026

Related Content

From Molecular Testing to Molecular Access—Bridging Rural-Urban Gaps in Advanced NSCLC

Erin Gillaspie, M.D. M.P.H., Joins Baptist Health Herbert Wertheim Cancer Institute as Chief of Thoracic Surgery

Erin Gillaspie, M.D., M.P.H., has joined Baptist Health Herbert Wertheim Cancer Institute and Baptist Health Cancer Care as chief of thoracic surgery.

  • by

  • November 3, 2026

  • 3 min
Two ‘forever chemicals’ associated with higher risk of aggressive breast cancer in NIH analysis

  • November 5, 2026